Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**6-Methylpurine** is a synthetic purine derivative and a toxic analog of adenine. It acts primarily as a bisubstrate inhibitor of enzymes that bind adenosyl moieties, notably inhibiting purine-nucleoside phosphorylase (EC 2.4.2.1)[2][3][8]. This inhibition can disrupt purine metabolism and may lead to the suppression of RNA and protein synthesis[3][8]. The compound has been widely used in biochemical research for studying nucleic acid function, enzyme assays related to purine metabolism, genetic engineering applications, and plant tissue culture[4]. In pharmaceutical development, it has been explored as an experimental anti-cancer agent due to its ability to interfere with nucleotide synthesis pathways[4]. However, it is not approved for clinical use in any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-methylpurine.